Effect of benralizumab on recurrent COPD exacerbations
D. Singh (Manchester, United Kingdom), G. Criner (Philadelphia, United States), A. Agusti (Barcelona, Spain), M. Bafadhel (Oxford, United Kingdom), J. Söderström (Gothenburg, Sweden), G. Luporini Saraiva (Gaithersburg, United States), Y. Song (Gaithersburg, United States), I. Licaj (Cambridge, United States), M. Jison (Gaithersburg, United States), U. Martin (Gaithersburg, United States), I. Psallidas (Cambridge, United Kingdom)
Source: International Congress 2022 – COPD clinical studies and exacerbations
Session: COPD clinical studies and exacerbations
Session type: Thematic Poster
Number: 3610
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Singh (Manchester, United Kingdom), G. Criner (Philadelphia, United States), A. Agusti (Barcelona, Spain), M. Bafadhel (Oxford, United Kingdom), J. Söderström (Gothenburg, Sweden), G. Luporini Saraiva (Gaithersburg, United States), Y. Song (Gaithersburg, United States), I. Licaj (Cambridge, United States), M. Jison (Gaithersburg, United States), U. Martin (Gaithersburg, United States), I. Psallidas (Cambridge, United Kingdom). Effect of benralizumab on recurrent COPD exacerbations. 3610
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|